Analyst Rating
based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Caplin Point Laboratories Ltd. An average target of ₹1882.67
Source: S&P Global Market Intelligence
Caplin Point Laboratories Ltd Share analysis
Caplin Point Laboratories Ltd price forecast by 3 analysts
Downside of
High
₹1980
Target
₹1882.67
Low
₹1800
Caplin Point Laboratories Ltd target price ₹1882.67, a slight downside of -6.06% compared to current price of ₹2004.15. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Caplin Point Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:51.22%
Forecast
Actual
Including amortisation and stock based compensations
Caplin Point Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:55.68%
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,987.15₹2,14452 Week's Low
52 Week's High
₹954₹2,144
| Returns % | |
| 1 Month Return | + 26.78 % |
| 3 Month Return | + 46.77 % |
| 1 Year Return | + 87.1 % |
| Market Stats | |
| Previous Close | ₹2,119.60 |
| Open | ₹2,085.00 |
| Volume | 6.68L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹16,111.44Cr |
Key Statistics
| P/E Ratio | 31.86 |
| PEG Ratio | 2.93 |
| Market Cap | ₹16,111.44 Cr |
| P/B Ratio | 3.97 |
| EPS | 49.67 |
| Dividend Yield | 0.75 |
| Sector | Pharmaceuticals |
| ROE | 22.63 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹16,111.44 Cr | 75.19% | 0.50 | ₹376 Cr | ₹1,466 Cr | |
| HOLD | ₹29,302.97 Cr | 122.43% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹14,937.56 Cr | 24.76% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹7,286.81 Cr | 9.82% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹13,011.31 Cr | 36.81% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Company Information
Share Price: ₹2004.15 per share as on 06 Sep, 2024 04:01 PM
Market Capitalisation: ₹16,111.44Cr as of today
Revenue: ₹458.96Cr as on June 2024 (Q2 24)
Net Profit: ₹124.92Cr as on June 2024 (Q2 24)
Listing date: 23 Jun, 2014
Chairperson Name: C C Paarthipan
| Organisation | Caplin Point Laboratories Ltd |
| Headquarters | Chennai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Caplin Point Laboratories Ltd
Caplin Point Labs Hits 52-Week High on Positive News - 05 Sep, 2024
Caplin Point Laboratories shares surged 10% to a new 52-week high, driven by heavy trading volumes and positive inspection results from Brazil's health agency. The stock has risen 40% in a month and over 90% in the past year, outperforming the Nifty 50 index.
Caplin Point Shares Surge After ANVISA Approval - 19 Aug, 2024
Caplin Point Laboratories' shares surged 15% to a record high following a successful ANVISA inspection with zero observations. The company emphasizes Brazil's importance in its expansion plans and has also received FDA approval for a product, showcasing strong financial performance.
Caplin Point Labs Passes ANVISA Inspection - 17 Aug, 2024
Caplin Point Laboratories' Chennai unit successfully cleared the Brazilian Health Regulatory Agency's inspection with zero observations. This achievement supports their expansion plans in Latin America, particularly in Brazil.
Caplin Point Labs Receives USFDA Approval for Eye Drops - 08 Aug, 2024
Caplin Point Laboratories' subsidiary received USFDA approval for Timolol Maleate Ophthalmic Solution, a generic equivalent of TIMOPTIC. The stock is down 1.5% but has gained 20% over three months and 57% year-on-year. Q1 FY25 net profit rose 19.8% YoY to ₹124.92 crore, with revenue up 16.1% YoY to ₹458.96 crore.
Caplin Point Reports Strong Q1 Growth - 07 Aug, 2024
Caplin Point Laboratories shares surged over 5% following robust Q1 FY25 results, with a 20% profit increase and 16% revenue growth year-on-year. The company also announced a final dividend and reappointment of its managing director.
Insights on Caplin Point Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 16 quarters, 269.88 Cr → 477.54 Cr (in ₹), with an average increase of 3.7% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, CAPLIPOINT has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 3.32% to 3.36% in Jun 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 1.06% to 1.32% in Jun 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, CAPLIPOINT has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 7 days, CAPLIPOINT stock has moved up by 6.3%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 11 quarters, 74.95 Cr → 123.97 Cr (in ₹), with an average increase of 4.9% per quarter
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 70.62% to 70.56% in Jun 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 24.95% to 24.57% in Jun 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 70.56% | ||
| Foreign Institutions | 3.36% | 0.98 | |
| Mutual Funds | 1.32% | 24.16 | |
| Retail Investors | 24.57% | ||
| Others | 0.19% | 411.05 |
Key Indicators
Caplin Point Laboratories Ltd Valuation
Caplin Point Laboratories Ltd in the last 5 years
Lowest (6.76x)
March 24, 2020
Today (31.86x)
September 6, 2024
Industry (59.14x)
September 6, 2024
Highest (34.97x)
February 15, 2018
Earnings and Dividends
Caplin Point Laboratories Ltd Earnings Results
Caplin Point Laboratories Ltd’s net profit jumped 19.86% since last year same period to ₹123.97Cr in the Q1 2024-2025. On a quarterly growth basis, Caplin Point Laboratories Ltd has generated 1.96% jump in its net profits since last 3-months.
Read More about Earnings ResultsCaplin Point Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Caplin Point Laboratories Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.35%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Caplin Point Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Caplin Point Laboratories Ltd shares.
Caplin Point Laboratories Ltd (CAPLIPOINT) share price today is ₹2004.15
Caplin Point Laboratories Ltd is listed on NSE
Caplin Point Laboratories Ltd is listed on BSE
- Today’s highest price of Caplin Point Laboratories Ltd is ₹2144.
- Today’s lowest price of Caplin Point Laboratories Ltd is ₹1987.15.
PE Ratio of Caplin Point Laboratories Ltd is 31.86
PE ratio = Caplin Point Laboratories Ltd Market price per share / Caplin Point Laboratories Ltd Earnings per share
Today’s traded volume of Caplin Point Laboratories Ltd(CAPLIPOINT) is 6.68L.
Today’s market capitalisation of Caplin Point Laboratories Ltd(CAPLIPOINT) is ₹16111.44Cr.
| Caplin Point Laboratories Ltd(CAPLIPOINT | Price |
|---|---|
52 Week High | ₹2144 |
52 Week Low | ₹954 |
Caplin Point Laboratories Ltd(CAPLIPOINT) share price is ₹2004.15. It is down -6.52% from its 52 Week High price of ₹2144
Caplin Point Laboratories Ltd(CAPLIPOINT) share price is ₹2004.15. It is up 110.08% from its 52 Week Low price of ₹954
| Caplin Point Laboratories Ltd(CAPLIPOINT | Returns |
|---|---|
1 Day Returns | -115.45% |
1 Month Returns | 26.78% |
3 Month Returns | 46.77% |
1 Year Returns | 87.1% |